Literature DB >> 710760

["T'orsade de pointe" and amiodarone (author's transl)].

L Veglia, T Scandiffio, G Guerricchio.   

Abstract

A long Q-T interval syndrome is described, followed by "torsade de pointe" and by irriducible ventricular fibrillation that is ascribed to a badly conducted therapy with amiodarone, in a patient affected by mitral valve disease, microcitaemia and hemolitic intercurrent moderate jaundice.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710760

Source DB:  PubMed          Journal:  G Ital Cardiol        ISSN: 0046-5968


  5 in total

Review 1.  Torsades de pointes: prevention and therapy.

Authors:  A Keren; D Tzivoni
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 2.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 3.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

4.  Adverse reactions during treatment with amiodarone hydrochloride.

Authors:  B McGovern; H Garan; E Kelly; J N Ruskin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-16

Review 5.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.